home / stock / pstv / pstv news

PSTV News and Press, PLUS THERAPEUTICS Inc. From 05/25/23

Stock Information
Company Name: PLUS THERAPEUTICS Inc.
Stock Symbol: PSTV
Market: NYSE
Website: plustherapeutics.com
Menu
PSTV PSTV Quote PSTV Short PSTV News PSTV Articles PSTV Message Board
Get PSTV Alerts

News, Short Squeeze, Breakout and More Instantly...
PSTV - Plus Therapeutics to Present at the 2023 Virtual June Investor Summit

AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced to...
PSTV - Plus Therapeutics regains Nasdaq minimum bid price compliance

2023-05-16 07:57:54 ET Clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, Plus Therapeutics ( NASDAQ: PSTV ) regains Nasdaq compliance. For the last 10 consecutive busines...

PSTV - Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements

AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announ...

PSTV - Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event

AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announ...
PSTV - Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials

New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium ( 186 Re) obisbemeda radiotherapeutic AUSTIN, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”...

PSTV - Plus Therapeutics Announces Reverse Stock Split

AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...

PSTV - Plus Therapeutics, Inc. (PSTV) Q1 2023 Earnings Call Transcript

2023-04-20 22:30:04 ET Plus Therapeutics, Inc. ( PSTV ) Q1 2023 Earnings Conference Call April 20, 2023 17:00 ET Corporate Participants Marc Hedrick - President and Chief Executive Officer Norman LaFrance - Chief Medical Officer Andrew Sims - Chief Financial ...
PSTV - Plus Therapeutics GAAP EPS of -$0.14 beats by $0.01

2023-04-20 16:07:51 ET Plus Therapeutics press release ( NASDAQ: PSTV ): Q1 GAAP EPS of -$0.14 beats by $0.01 . For further details see: Plus Therapeutics GAAP EPS of -$0.14 beats by $0.01

PSTV - Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Plus completes Phase 1/Part A of the ReSPECT-LM trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company d...

PSTV - Plus Therapeutics Completes Enrollment of the Original Three Patients Required for Cohort 8 of ReSPECT-GBM Phase 1/2a Trial

AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today anno...
Previous 10 Next 10